期刊
BIOENGINEERING & TRANSLATIONAL MEDICINE
卷 8, 期 2, 页码 -出版社
WILEY
DOI: 10.1002/btm2.10453
关键词
cancer immunotherapy; cytokine; drug delivery; layer-by-layer; nanomedicine; nanoparticle
Ovarian cancer is difficult to treat and has been resistant to immunotherapies. However, a new study shows that systemically delivered nanoparticles can effectively target and engage the immune system as a treatment in multiple ovarian tumor models, including those with low immune response. This therapy demonstrates reduced toxicity and maintained anti-tumor efficacy, resulting in a 30% complete survival rate.
Ovarian cancer is especially deadly, challenging to treat, and has proven refractory to known immunotherapies. Cytokine therapy is an attractive strategy to drive a proinflammatory immune response in immunologically cold tumors such as many high grade ovarian cancers; however, this strategy has been limited in the past due to severe toxicity. We previously demonstrated the use of a layer-by-layer (LbL) nanoparticle (NP) delivery vehicle in subcutaneous flank tumors to reduce the toxicity of interleukin-12 (IL-12) therapy upon intratumoral injection. However, ovarian cancer cannot be treated by local injection as it presents as dispersed metastases. Herein, we demonstrate the use of systemically delivered LbL NPs using a cancer cell membrane-binding outer layer to effectively target and engage the adaptive immune system as a treatment in multiple orthotopic ovarian tumor models, including immunologically cold tumors. IL-12 therapy from systemically delivered LbL NPs shows reduced severe toxicity and maintained anti-tumor efficacy compared to carrier-free IL-12 or layer-free liposomal NPs leading to a 30% complete survival rate.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据